Together, these studies uncover novel compensatory pathways that may be involved ... Key among these is the activation of signaling by RHO (another member of the RAS superfamily) and the up ...

RTKs can activate Ras, a protein that is tethered to the plasma ... such as the alteration of key proteins and changes in gene transcription. Signal binding to membrane receptor tyrosine kinases ...

About 20% of patients with RASopathies have HCM; RASopathy-associated HCM is often caused by genetic mutations in the RAS/MAPK signaling pathway, which regulates cell growth and development. It is ...

Trametinib, a mitogen-activated protein kinase (MEK) inhibitor, reduces mortality and morbidity in children with severe hypertrophic cardiomyopathy (HCM) caused by pathogenic variants in ...

in tumors expressing different RAS, RAF, or NF1 mutants. We have shown that tumors with HER2 amplification or PI3K mutation are selectively dependent for growth on the PI3K pathway and are sensitive ...

Discover Trametinib as a promising treatment for severe hypertrophic cardiomyopathy in children with RASopathies.

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK ...